Cigna (CI) Stock Forecast & Price Target

Cigna Group's positive outlook is supported by anticipated strong growth in its Evernorth segment, which is expected to enhance patient satisfaction, lower costs, and improve health outcomes, thereby complementing its Cigna Healthcare business for cross-selling opportunities. Projections indicate that the Healthcare segment’s adjusted operating income (AOI) could grow at the higher end of its long-term target of 7%-10%, bolstered by stop loss margin recovery and favorable pricing actions, despite some challenges in membership levels. Additionally, the expected strong free cash flow positions Cigna favorably for capital deployment to expand service offerings, contributing to an overall favorable valuation and growth trajectory.

Cigna Group faces a negative outlook primarily due to anticipated declines in its Evernorth Adjusted Operating Income (AOI), which is projected to fall from $3,506 million in CY25 to approximately $2,749 million in CY26, reflecting a year-over-year decrease of $758 million. This decline is attributed to multiple factors, including the expected erosion of PBM margins as the company transitions to a rebate-free model, which could reduce earnings by $500 million to $600 million in 2026. Furthermore, challenges such as slowing biosimilar adoption, client losses, and risks associated with healthcare cost management exacerbate the company's financial outlook, particularly in the context of modest growth prospects within the U.S. commercial market.